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Abstract
SCYX-7158, an oxaborole, is currently in Phase I clinical trials for the treatment of human
African trypanosomiasis. Here we investigate possible modes of action against Trypano-
soma brucei using orthogonal chemo-proteomic and genomic approaches. SILAC-based
proteomic studies using an oxaborole analogue immobilised onto a resin was used either in
competition with a soluble oxaborole or an immobilised inactive control to identify thirteen
proteins common to both strategies. Cell-cycle analysis of cells incubated with sub-lethal
concentrations of an oxaborole identified a subtle but significant accumulation of G2 and
>G2 cells. Given the possibility of compromised DNA fidelity, we investigated long-term
exposure of T. brucei to oxaboroles by generating resistant cell lines in vitro. Resistance
proved more difficult to generate than for drugs currently used in the field, and in one of our
three cell lines was unstable. Whole-genome sequencing of the resistant cell lines revealed
single nucleotide polymorphisms in 66 genes and several large-scale genomic aberrations.
The absence of a simple consistent mechanism among resistant cell lines and the diverse
list of binding partners from the proteomic studies suggest a degree of polypharmacology
that should reduce the risk of resistance to this compound class emerging in the field. The
combined genetic and chemical biology approaches have provided lists of candidates to be
investigated for more detailed information on the mode of action of this promising new drug
class.
Author Summary
The mode of action of a new class of boron-containing chemicals (the oxaboroles), cur-
rently under development for the treatment of human African trypanosomiasis, is
unknown. Here we identify a number of potential candidate proteins that could be
involved either in the mode of action of these compounds or in the mechanism of
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resistance. This information could prove critical in protecting the compounds against
resistance emerging in the field as well as opening up new avenues for drug discovery.
Introduction
Human African trypanosomiasis (HAT) is caused by two subspecies of the unicellular parasite
Trypanosoma brucei, an infection which is transmitted by the bite of a tsetse fly. HAT pro-
gresses through a haemo-lymphatic stage into a meningo-encephalitic stage [1] and has a fatal-
ity rate close to 100% if left untreated [2]. The disease is also a key factor in maintaining the
poverty cycle, and patients are often discriminated against or abandoned [3]. The reporting of
new cases of HAT has fallen to below 7,000 in 2011 [4]. However, the disease has previously
resurged from even lower levels in the 1980s and 1990s [5]. Current estimates place 70 million
people at risk with more than 5 million living in areas of high or very high risk for contracting
HAT [4].
T. brucei gambiense is responsible for around 98% of reported cases [5], and has been tar-
geted by the World Health Organization for elimination by 2020. However, elimination of T.
brucei rhodesiense, which has epidemic potential, is not feasible due to its animal reservoir [5].
The tsetse fly vector also presents significant risks to disease control in that climate change may
allow the vector to invade new geographical regions [6], and sexual recombination, which
occurs within the vector, could allow rapid transfer of drug resistance and virulence factors [7].
Hence, whilst improvements in control have been achieved, there are several risk factors that
could lead to resurgence of the disease [8,9].
Existing drugs are highly unsatisfactory due to toxicity, mode of administration and efficacy
[8]. The ease of developing resistance to both components of the nifurtimox / eflornithine com-
bination therapy (NECT, the newest treatment to enter the clinic) [10] is also a major concern
[11,12]. Moreover, due to its status as a neglected disease of declining incidence, the current
drug discovery pipeline for HAT is far from robust [13]. Thus, development of new drugs
remains a critical task.
Recent advances have included the entry of fexinidazole into phase II/III trials against HAT
(ongoing) [14] and the identification of oxaboroles as a class of compounds active against T.
brucei by a collaboration between the Drugs for Neglected Disease initiative, Anacor Pharma-
ceuticals and SCYNEXIS [15]. One member of this class, SCYX-7158, shown to be effective in
the meningo-encephalitic stage of HAT [16], entered phase I clinical trials in March 2012 and
studies, including safety profiling, are ongoing (DNDI diseases and projects portfolio accessed
14/08/15 www.dndi.org/diseases-projects/portfolio/oxaborole-scyx-7158]).
Oxaborole compounds have been demonstrated to act via inhibition of leucyl RNA synthe-
tase as anti-pneumococcal agents [17] and anti-fungal agents [18]. They can also form adducts
with cis-diols in sugars and have been shown to inhibit other enzymes such as phosphodiester-
ases, β-lactamases and kinases (see review [19]). However, the mode of action against African
trypanosomes has not been determined. This information would inform the selection of appro-
priate partner compounds to protect against resistance, and could also open up novel areas of
drug discovery.
Our objective was to apply genomic sequencing and chemo-proteomic approaches [20] to
facilitate mode of action studies on the oxaborole series, an approach which has been successful
with other antitrypanosomal compounds [21,22]. Here, we report the use of two orthogonal
methods (proteomic studies using affinity chromatography and stable isotope labelling by
amino acids in cell culture [SILAC]; and whole genome sequencing of sensitive and drug-
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resistant cell lines) to produce lists of candidate targets for oxaborole compounds that will be
pursued in future work. Our experiments suggest a high level of polypharmacology that could
protect the oxaborole class from resistance emerging in the field.
Materials and Methods
Chemicals
All chemicals were obtained from Sigma-Aldrich (Gillingham, UK) unless otherwise indicated.
Amino acids for SILAC labelling (4,4,5,5-D4 L-Lysine and U-13C6 L-Arginine) were obtained
from CK Gas Products (Hampshire, UK). PBS was formulated in-house. Foetal bovine serum
for HMI9T was obtained from PAA Laboratories (Yeovil, UK), dialysed foetal bovine serum
for SILAC-labelling was obtained from Life Technologies (Paisley, UK). IMDM for SILAC–
labelling (lacking Arginine and Lysine) was obtained from Thermo Scientific (Basingstoke,
UK). The cOmplete EDTA-free protease inhibitor cocktail was obtained from Roche Diagnos-
tics (West Sussex, UK).
Cell culture
Bloodstream-form T. brucei ‘single marker’ cells [23] were cultured at 37°C with 5% CO2 in
HMI9T medium [24]. Cells were counted using a CasyCounter model TT (Roche Innovatis,
Reutlingen) and maintained at densities below 5×106 ml−1, sub-culturing as necessary. EC50
determinations were carried out using a resazurin-based assay, and means weighted to the
standard error calculated as previously described [25,26].
SILAC-labelling was carried out using an adapted HMI11 [27]; T. brucei log-phase cells in
HMI9T medium were washed in PBS and seeded at 1×104 ml−1 into HMI11-SILAC + R6K4 as
described previously [28]. Following 3 days growth to*1×106 ml−1, cells were harvested by
centrifugation, washed in ice-cold PBS, and resuspended in PBS at 1.25×109 ml−1. Four parts
cell suspension was mixed with one part 5× lysis buffer (25% glycerol; 30 mMMgCl2; 4% IGE-
PAL CA-630 (octylphenoxy poly(ethyleneoxy)ethanol); 5 mMDTT), cOmplete protease
inhibitor cocktail added to 1× concentration and the sample freeze-thawed three times.
DNase-I was added to 1 μg ml−1, the mixture incubated on ice for 5 min, vortexed for 10 s and
clarified by centrifugation at 20,000 g for 1 h at 4°C. The supernatant was divided into 500 μl
aliquots, adjusted to 5 mg ml−1 with 1 × lysis buffer, snap frozen, and stored at -80°C prior to
subsequent processing.
Synthesis of oxaboroles and immobilisation to paramagnetic beads
SCYX-6759 and oxaborole-1 were prepared using previously published methodology [29]. Full
experimental details for the synthesis of the oxaboroles utilised in this study are given in the
Supporting Information (S1 Text). Beads derivatised with an oxaborole, or control compound
were prepared as follows. The storage solvent was removed from commercial NHS functiona-
lised magnetic beads (Thermo Scientific) and the beads washed and resuspended in anhydrous
DMSO (150 μl [mg resin]−1). The amine-containing compound (7 nmol [mg resin]−1) and
DIPEA (14 nmol [mg resin]−1) were then added and the resin gently agitated for 24 h at room
temperature. After which the reaction solvent was removed, and the beads washed and resus-
pended in anhydrous DMSO (150 μl [mg resin]−1). Ethanolamine (70 nmol [mg resin]−1) and
DIPEA (70 nmol [mg resin]−1) were then added and the resin gently agitated for 24 h at room
temperature. The reaction solvent was then removed and the resin washed with DMAc, prior
to storage in the same solvent. Note, the incubation step with an amine-containing compound
is omitted when preparing ‘blank’ ethanolamine-capped beads.
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Chemical proteomic profiling
Lysates were pre-cleared by incubation with ethanolamine-capped paramagnetic beads (0.2
mg) for 30 min at 4°C, after which the supernatant was transferred to a new sample tube along
with a 50 μl wash. For competition experiments, oxaborole-1 in DMSO (1 μM final concentra-
tion) or a DMSO control was added (0.5% DMSO final) and incubated with mixing for 30 min
at 4°C. Subsequently, 0.2 mg of oxaborole-resin (Fig 1) was added to each sample and incu-
bated for a further 60 min at 4°C. The beads were isolated using a magnet, washed twice with
lysis buffer and united into a single sample tube. The beads were further washed three times
with PBS, and bead-bound proteins were eluted with NuPAGE LDS buffer (Invitrogen) con-
taining 50 mM DTT for 5 min at 95°C. For comparison of the oxaborole resin and control
resin, pulldowns were performed in a similar manner in the absence of soluble compound.
Polyacrylamide gel electrophoresis
Eluted samples were subjected to electrophoresis on a NuPAGE bis-Tris 10% acrylamide gel
until the dye front had entered about 1 cm into the gel. The proteins were stained with Instant-
Blue (Expedeon), and the entire stained area excised and subjected to in-gel digestion for 18 h
at 37°C with 12.5 μg ml−1 trypsin gold (Promega) in 10 mMNH4HCO3, 10%MeCN. Tryptic
peptides were recovered in 45% MeCN, 1% formic acid and lyophilized prior to analysis.
Mass spectrometry data acquisition and processing
Liquid chromatography tandem mass spectrometry was performed by the Fingerprints Proteo-
mic Facility at the University of Dundee, as described previously [28]. Data was processed
using MaxQuant [30] version 1.3.0.5 which incorporates the Andromeda search engine [31].
Proteins were identified by searching a protein sequence database containing T. brucei brucei
927 annotated proteins (Version 4.0, downloaded from TriTrypDB [32], http://www.tritrypdb.
org/) supplemented with the VSG221 sequence and frequently observed contaminants (por-
cine trypsin, bovine serum albumin and mammalian keratins) that contains a total of 10,081
protein sequences. Search parameters specified an MS tolerance of 6 ppm, an MS/MS tolerance
at 0.5 Da and full trypsin specificity, allowing for up to two missed cleavages. Carbamido-
methylation of cysteine was set as a fixed modification and oxidation of methionine residues,
N-terminal protein acetylation and N-pyroglutamate were allowed as variable modifications.
Peptides were required to be at least 7 amino acids in length and a MaxQuant score>5, with
false discovery rates (FDRs) of 0.01 calculated at the levels of peptides, proteins and modifica-
tion sites based on the number of hits against the reversed sequence database. SILAC ratios
were calculated using only peptides that could be uniquely mapped to a given protein group,
and required a minimum of two SILAC pairs. To account for any errors in the counting of the
number of cell numbers mixed, the distribution of SILAC ratios was normalised within Max-
Quant at the peptide level so that the median of log2 ratios is zero [30]. Data were visualized
using Perseus 1.3.0.4 (www.perseus-framework.org) and further information on the identified
proteins was obtained from TriTrypDB [32] (http://www.tritrypdb.org).
Cell-cycle analysis
T. brucei cultures (50 ml) were seeded at 5×105 ml−1 in the presence of 225 nM Oxaborole-1
(5× EC50). Samples (4 ml) were taken at 0, 14, 20 and 28 h, collected by centrifugation at 850 g
for 10 min and processed essentially as previously described [33]. Briefly, cells were washed in
1 ml PBS containing 1% FBS, the supernatant was removed and cells resuspended in the resid-
ual volume. Cells were fixed with 1 ml ice cold 70% ethanol, adjusted to 5×105 ml−1 and washed
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twice with PBS containing 1% FBS. Cells were resuspended in 400 μl staining solution (PBS
containing 1% FBS, 50 μg ml−1 propidium iodide, 50 μg ml−1 RNase A), stained for 20 min at
room temperature before being analysed by flow cytometry as previously described [33].
Generation of oxaborole-resistant cell lines
Oxaborole-resistant T. brucei were generated in three independent flasks by sub-culturing in
the presence of increasing concentrations of Oxaborole-1. Beginning at the sub-lethal concen-
tration of 20 nM, the process was continued until the cells were growing in 500 nM
(*10 × original EC50). Throughout the process, increasing concentrations of Oxaborole-1
were attempted once the cells were displaying cell growth and motility similar to a control
grown in the absence of the drug. After 180 days, cells were cloned by limiting dilution in the
presence of 500 nM Oxaborole-1 to yield independent clones from each of the three flasks.
The three resistant clones were diluted 1000-fold into media without Oxaborole-1 and sub-
cultured as necessary over a two month period. EC50 determinations were carried out to indi-
cate whether resistance had been maintained in the absence of exposure to Oxaborole-1.
Genomic sequencing and analysis
Genomic DNA was prepared from five T. brucei lines, i.e. the parental clone Lister 427 (SM),
three oxaborole-resistant clones (clone 1, 2, and 3), and a drug-resistance revertant clone (clone
1R). For each sample, 0.6–2 μg of genomic DNA was used to produce standard Illumina librar-
ies of 400–600 base pairs (bp) [34]. Sequencing was carried out on an Illumina HiSeq 2000
sequencer according to the manufacturer’s standard sequencing protocol and yielded 22.8–29.6
Fig 1. Structure of oxaboroles and affinity chromatography resins.
doi:10.1371/journal.pntd.0004299.g001
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million reads of 100 bp length per library. These data sets represented a nominal sequencing
coverage of the T. brucei genome (35Mb) of approximately 65.2- to 84.6-fold. The Illumina data
were aligned against the T. brucei brucei TREU927 reference genome [35] assembly using
SMALT v0.7.4 (http://www.sanger.ac.uk/resources/software/smalt/). For variant calling, the
alignment was run employing an exhaustive search (-x) and with parameters wordlen = 13 (-k),
skipstep = 1 (-s), minscor = 0.8 (-m), and insertmax = 1000 (-i). To assess relative read coverage
and copy number variations (CNVs), the alignment runs were repeated using the above param-
eters with repetitive mapping (-r) enabled which results in read pairs with multiple equally good
alignment positions being aligned to one of these locations at random. Variants were called
using SAMtools v0.1.19 mpileup (-Q 15 for baseQ/BAQ filtering) and BCFtools [36]. To exclude
the hypervariable subtelomeric regions, only variants found in the following chromosomal core
regions were included in the downstream analyses: Tb927_01_v4:202,695–988,120;
Tb927_02_v4:259,723–1,161,408; Tb927_03_v4:146,614–1,602,829; Tb927_04_v4:80,380–
1,467,268; Tb927_05_v4:72,088–1,366,595; Tb927_06_v4:111,409–1,414,033; Tb927_07_v4:
26,571–2,177,541; Tb927_08_v4:135,192–2,476,033; Tb927_09_v4:325,850–2,394,987;
Tb927_10_v5:55,698–3,993,940; Tb927_11_01_v4:36,585–4,482,610. SNP calls were further fil-
tered for all of the following: for a minimum of 8 "high-quality" base calls ("DP4"); for a mini-
mum phred-scale QUAL score of 20; for a maximum phred-scale likelihood of the best
genotype call of 5 ("PL1"); for a minimum phred-scale likelihood of the second best genotype
call of 10 ("PL2"); for a minimum strand bias P-value of 0.01 (first of "PV4"); for a maximum
ratio of conflicting base calls for homozygous genotypes of 5%; and, for positions with a mini-
mum and maximum read depth of three times the median read depth observed for that chro-
mosome: for a minimummapping quality of 20; and for a minimum distance of 10 nucleotides
from the nearest INDEL call. Files in Variant Call Format (VCF) listing all 206,417 genomic
positions at which any one of the five sequenced parasite lines had a variant call are available in
the supplementary material (S1–S5 Datasets). The illustrations showing the location of genes
along chromosomal regions in Figure CNVs was generated usingWeb-Artemis (http://www.
genedb.org/web-artemis/).
Accession numbers
The raw sequence data are available under the following accession numbers at the European
Nucleotide Archive (http://www.ebi.ac.uk/ena): parent: ERS136142; resistant clone 2:
ERS136134; resistant clone 3: ERS136135; resistant clone 1: ERS136145; revertant clone of
clone 1: ERS136137. The raw and processed mass spectrometry data have been deposited with
the ProteomeXchange Consortium [37] (http://www.proteomexchange.org/) via the PRIDE
partner repository under the identifier PXD002848.
Results and Discussion
Chemical synthesis / immobilisation
The synthesis of SCYX-6759 and Oxaborole-1 was readily achieved using published procedures
[29]. Initial attempts to immobilise the oxaborole scaffold involved the direct attachment of
biotin (for use in conjunction with a streptavidin resin) to the aniline functionality to give Oxa-
borole-2 (Fig 1 and S1 Fig). However, subsequent biological assay demonstrated that Oxabor-
ole-2 was only weakly active against T. brucei (EC50 15 μM) compared to SCYX-6759 (EC50
0.16 μM), Oxaborole-1 (EC50 0.064 μM) or SCYX-7158 (EC50 0.79 μM, data from [16,38]).
Therefore, a small number of analogues retaining the benzamide functionality of SCYX-6759
and SCYX-7158 were prepared (one of which is shown in S2 Fig). Oxaborole-3, which contains
a polyethyleneglycol linker in themeta position of the benzamide was found to retain activity
Studies on the Mode of Action of Oxaboroles
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in the bloodstream form T. brucei assay (EC50 0.086 μM). The carbamate protecting group of
Oxaborole-3 was subsequently removed and the resultant primary amine reacted to prepare an
amide of biotin (Oxaborole-Biotin, S2 Fig), which in this case was found to be bioactive (EC50
0.40 μM). An analogue of SCYX-6759, where the oxaborole bicycle was replaced with a phtha-
lide bicycle (Control-1) was prepared and found to be inactive against T. brucei. Therefore, a
control biotin conjugate (Control-Biotin) was prepared in an analogous fashion to Oxaborole-
Biotin (S3 Fig). Pilot chemical proteomics studies suggested that the use of a biotin-conjugate/
streptavidin bead system was sub-optimal. As a result, the linker containing oxaborole and
control analogues were instead attached to paramagnetic beads via an amide linkage to give an
Oxaborole-Resin and a Control-Resin respectively (Fig 1 and S2 and S3 Figs).
Chemical proteomic profiling
In order to directly profile the proteins that bound to the Oxaborole-Resin, chemical proteomic
profiling was undertaken using two orthogonal strategies that utilised SILAC quantitation to
eliminate non-specific binding proteins. In these experiments parasites are grown in identical
media where one contains “light” and the other “heavy” amino acid isotopes (in this case argi-
nine and lysine). After several rounds of cell division, the two populations are identical except
for the differential labelling of the proteome with either light or heavy isotopes. After undergo-
ing differential processing, the two samples are combined and the ratio of heavy to light peptide
from each individual protein determined by mass spectrometry. Proteins that are specifically
enriched by the differential treatment will have a heavy to light ratio not equal to 1, whereas
proteins affected equally with have a ratio = 1 (or binary logarithm of 1 = zero).
In the first strategy, the profile of proteins from T. brucei cell lysates that bind the beads in
the presence (heavy label) or absence (light label) of soluble inhibitor was quantified (Fig 2).
Non-specific binders will be unaffected by the presence of soluble compound, thus will produce
an equal heavy to light ratio (log2 H/L = 0). In contrast, the specific binders will bind Oxabor-
ole-1 in the pre-incubation step, making them unavailable to bind to the immobilised oxabor-
ole, resulting in a low heavy to light ratio (log2 H/L< 0) (Fig 2A, upper pair).
In the second strategy, an inactive Control-Resin was prepared (Fig 1 and S3 Fig). The pro-
file of proteins from T. brucei cell lysates that bind the Control-Resin (heavy label) or Oxabor-
ole-Resin (light label) can then be quantified (Fig 2). Proteins that bind non-specifically, or
whose binding is not related to activity, produce an equal heavy to light ratio (log2 H/L = 0),
whereas proteins whose binding correlates with activity will have a low heavy to light ratio
(log2 H/L< 0) (Fig 2A, lower pair).
The results of the two orthogonal strategies are shown in Fig 2 and Table 1, with the full
data presented in the supplementary material (S1 Table). The binding of a subset of proteins
was prevented by the presence of the soluble compound (Fig 2B), with 42 proteins displaying
greater than a four-fold reduction in binding (log2 H/L< -2). In the orthogonal strategy, a sub-
set of 24 proteins displayed greater than a four-fold reduction in binding (log2 H/L< -2) to the
Control-Resin compared to the Oxaborole-Resin (Fig 2C). Comparing the profile of the pro-
teins quantified in both experiments revealed a strong correlation (Pearson 0.841) between the
proteins that are displaced by Oxaborole-1 and those that bind only the Oxaborole-Resin and
not the Control-Resin (Fig 2D). The 14 proteins that display greater than four-fold selectivity
in each experiment, presented in Table 1, can be considered to be specific targets of Oxaborole-
1. The number of specific targets identified and the lack of discernible commonality strongly
suggest that oxaboroles display considerable polypharmacology, and provide too great a num-
ber to investigate systematically as individual targets.
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Cell-cycle analysis
FACS analysis of T. brucei cells incubated with 225 nM Oxaborole-1 (5× EC50) indicated a sta-
tistically significant increase in the proportion of G2 and>G2 cells compared to the untreated
control (Fig 3). These increases probably result from re-replication of DNA in the absence of
cytokinesis. DNA re-replication has been seen in a variety of mutant T. brucei cell lines; how-
ever, it is possible that the cytokinesis defect is an indirect effect [40]. Indeed perturbation of
several processes results in inhibition of cytokinesis including flagellar attachment, GPI biosyn-
thesis, Golgi duplication and kinetoplast duplication [41,42]. Given such an impact on DNA
fidelity, we wanted to investigate the genomic effects of resistance to the oxaborole.
Fig 2. Quantitative chemical proteomic profiling of oxaborole targets. A–Schematic of proteomic profiling strategies representing ligand competition
experiment (top) and resin comparison experiment (bottom). B–Drug competition experiment. SILAC-labelled T. brucei cell lysates were incubated with
10 μMOxaborole-1 (heavy label) or DMSO control (light label), prior to enrichment of protein with Oxaborole-Resin.C–Comparison of analogue-bound resin.
Proteins were enriched from SILAC labelled T. brucei cell by Oxaborole-Resin (light label) or Control-Resin (heavy label).D–Correlation of the proteins
quantified by the two strategies. A colour key is included to show the range of enrichment of identified proteins.
doi:10.1371/journal.pntd.0004299.g002
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Generation of oxaborole-resistant cell lines
In order to investigate the ease with which resistance to the oxaborole could occur, we gener-
ated three independent clones of T. brucei able to sustain growth in 500-nM Oxaborole-1 (Fig
4A). This process took 180 days for all three cell lines to achieve the target of growth in 500 nM
Oxaborole-1. A single clone was chosen for each resistant line, and sensitivity to the oxaborole
measured by EC50 (Fig 4B). The resulting EC50 shifts were between 5–8 fold compared to the
sensitivity of the parental cell line to Oxaborole-1. A similar process using nifurtimox gener-
ated T. brucei able to grow in>20× EC50 after 140 days [11], although after cloning, the shift in
sensitivity to nifurtimox was 8-fold. T. brucei resistant to eflornithine, pentamidine and the
methionine tRNA synthetase inhibitor 1433, have all been generated to grow at 32× their EC50
concentrations within 120 days or less [43]. Whilst a major motive for investigating mode of
action was to aid the protection of the oxaborole class from resistance in the field, these results
indicate greater resilience to resistance to the oxaborole class than drugs currently used in the
field as well as compounds in development.
Reversion of oxaborole-resistance
Following two weeks incubation in the absence of Oxaborole-1, an EC50 determination showed
loss of resistance from cell line 1 (EC50 value of 123 ± 12 nM compared to 530 ± 21 nM). This
cell line was cloned by limiting dilution and EC50 determinations were carried out on five
clones. All of the clones showed loss of resistance, the clone with greatest loss of resistance
(termed clone 1R) had an EC50 value of 83 ± 2 nM (weighted mean of two determinations).
Culture of resistant cell lines 2 and 3 failed to show any loss of resistance over eight weeks in
the absence of Oxaborole-1.
Table 1. Specific binding partners of the Oxaborole-Resin revealed by proteomic profiling.
GeneDB IDs Product Function Ligand
competition
Resin
comparison
Log2 H/L Log2 H/L
Tb927.9.6870* RNA-binding protein, putative (RBSR1) Possible pre-mRNA splicing -5.68 -2.98
Tb927.10.3200* U2 splicing auxiliary factor, putative (U2AF35) pre-mRNA splicing -5.06 -2.53
Tb927.8.3060* cytosolic leucyl aminopeptidase, putative,metallo-
peptidase, Clan MF, Family M17
proteolysis -4.68 -2.70
Tb927.8.4810 prohibitin 1 (PHB1) mitochondrial biogenesis -3.64 -3.57
Tb927.10.2890*; Tb11.
v5.0650
enolase glycolysis -3.54 -2.57
enolase, putative
Tb927.9.8720 fructose-1,6-bisphosphatase (FBPase) gluconeogenesis -3.52 -3.22
Tb927.6.1570* 2-hydroxy-3-oxopropionate reductase, putative valine, leucine and isoleucine
degradation
-3.14 -2.77
Tb927.11.11250 cytosolic malate dehydrogenase (cMDH) glycolysis -2.98 -2.26
Tb927.4.2080* C2 domain containing protein (CC2D) ﬂagellum biosynthesis -2.96 -2.29
Tb927.6.4280*;
Tb927.6.4300
glyceraldehyde 3-phosphate dehydrogenase,
glycosomal (GAPDH)
glycolysis -2.90 -2.59
Tb927.11.11680* 2-oxoglutarate dehydrogenase E2 component,
putative
tricarboxylic acid cycle -2.79 -2.51
Tb927.4.1890 hypothetical protein, conserved -2.55 -2.02
Tb927.7.1310* hypothetical protein, conserved -2.42 -2.21
*Abnormal RIT-SEQ growth phenotype in bloodstream forms at either day 3 or day 6 or both [39].
doi:10.1371/journal.pntd.0004299.t001
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The apparent greater instability of resistance in resistant cell line 1 was consistent with prob-
lems encountered when attempting to revive frozen cells. Stabilated cells revived from resistant
cell lines 2 and 3 grew at the same rate as the parental cell line. However, cells from resistant
cell line 1 showed little motility, although there were no abnormalities in gross morphology by
light microscopy. After 7–14 days growth was regained, however after a single passage and
three days of growth to select for healthy cells, resistance had been lost. This suggests at least
two routes of resistance, an unstable mechanism and one or more stable mechanisms. Greater
stability could be conferred by a gene segment being totally lost rather than silenced, or geno-
mic amplification carrying a significant fitness cost compared to one with no such cost.
Fig 3. Cell cycle analysis following treatment with Oxaborole-1.
doi:10.1371/journal.pntd.0004299.g003
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Genomic sequencing
To identify genetic determinants that may be involved in drug resistance to the oxaborole class,
we sequenced the genomes of the susceptible parental strain Lister 427, the three drug-resistant
clones and the revertant cell line. We found striking copy number variations (CNVs) between
the parasite clones, ranging from apparent whole chromosome duplications to CNVs affecting
regions of approximately 5 kb to 15 kb in length (Fig 5). For example, chromosome 1 occurs in
three instead of the usual two copies in the genome of clones 1 and 1R (Fig 5A), while chromo-
some 4 displays an elevated copy number in clone 2 (Fig 5B). In addition, a short region of
chromosome 4 of approximately 5.5 kb is further duplicated in this cell line (Fig 5C), thereby
providing further complete copies of the two genes CPSF3 (a putative cleavage and polyadeny-
lation specificity factor subunit, Tb927.4.1340) and glx2-2 (a glyoxalase, Tb927.4.1350)
(Table 2). In contrast, two short regions on chromosome 6 and chromosome 10 in drug-resis-
tant clone 3 have lost one of their two alleles (Fig 5D and 5E). Interestingly, the deleted regions
are flanked in both cases by shorter regions with nearly 100% sequence identity: on chromo-
some 6 the central, deleted region of 5.1 kb is flanked by two near-identical regions of approxi-
mately 4.8 kb each, whereas on chromosome 10 it is a central region of 12.9 kb that is flanked
by two near-identical regions of approximately 3.1 kb each (Fig 5D and 5E). This suggests
homologous crossover as the mechanism of DNA deletion in these cases. These deletions
directly affect over a dozen genes (Table 2) and render the affected regions hemizygous, an
observation that is confirmed by the loss of a second allele in the genotype of some of these
genes (S2 Table).
The comparison of genotype assignments between the drug-resistant lines and those of the
parental strain uncovered in total 78 single nucleotide polymorphisms (SNPs) in 66 genes. Of
these, 41 in 38 genes are predicted to result in non-synonymous amino acid changes that could
potentially contribute to the observed drug resistance phenotypes (S2 Table). Only one SNP
was common to all four clones (receptor-type adenylate cyclase GRESAG 4, putative), but no
SNP was common to all 3 resistant clones and absent from the revertant clone, as might be
expected if a single point mutation in a single gene was responsible for resistance. Likewise, the
Fig 4. Generation of cell lines resistant to Oxaborole-1. A. Stepwise generation of resistance to oxaborole.B. Representative drug sensitivity plots. The
parental cloned line had an EC50 value of 64.4 ± 1.8 nM and the resistant clones 1, 2 and 3 had EC50 values of 530 ± 21, 390 ± 17 and 340 ± 27, nM,
respectively. Data are the weighted mean of three independent determinations.
doi:10.1371/journal.pntd.0004299.g004
Studies on the Mode of Action of Oxaboroles
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004299 December 18, 2015 11 / 18
Fig 5. Copy number variations (CNVs) in the drug-resistant and -revertant parasite lines identified by whole genome sequencing. The read
coverage plots show the relative read depth across selected chromosomal regions in the different parasite lines. (A, B) The panels depict the relative read
coverage across the core regions of chromosomes 1 and 4, analysed in windows of 12 kb width, by plotting the ratio of the median read depth observed in a
given window over the median read depth of all chromosomes for that parasite line. A relative read depth of 1.5 therefore represents a 50% copy number
increase of the respective chromosome compared to the rest of the genome, which indicates an absolute copy number increase from two to three in the
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small ubiquitin-related modifier (SUMO) contained different SNPs in all 4 clones. SUMOyla-
tion regulates a wide variety of cellular processes, including transcription, mitotic chromosome
segregation, DNA replication and repair and ribosomal biogenesis [44,45] and offers an attrac-
tive explanation for the chromosomal abnormalities described above. Knock down of SUMO
in procyclic forms of T. brucei results in arrest in G2/M phase of the cell cycle as observed here
[46]. In the case of clone 3, the SNP results in replacement of the initiator methionine residue
with an isoleucine. Inspection of the flanking region of SUMO revealed no upstream in-frame
methionine and the next downstream methionine is at residue 50 in this 114 amino acid pro-
tein. Based on the solution structure of T. brucei SUMO [47], the truncated protein is likely to
diploid parasite genome. (C-E) These panels depict the relative read coverage across selected chromosomal regions, analysed in windows of 600 bp width,
by plotting the log2-based ratio of the median read depth observed in a given window over the median read depth of the entire core region of that
chromosome for that parasite line. A log2-based relative read depth of 1 therefore represents a 100% copy number increase of the respective region
compared to the rest of that chromosome, whereas a log2-based relative read depth of -1 indicates a 50% reduction in read depth which is likely due to the
loss of one of the two alleles in that region (hemizygosity). In both cases of allele loss, the central area with 50% diminished read depth is flanked by two
regions that are approximately 99% identical to one another (D, E). The location of genes along chromosomal regions is indicated below the graphs (C-E).
Note the variable but highly reproducible (across the different parasite lines) nature of the read coverage which is in part caused by differences in sequence
read mapping efficiency across the genome especially in regions of repetitive sequence.
doi:10.1371/journal.pntd.0004299.g005
Table 2. Genes affected by copy number variations (CNVs) observed in the parasite lines.
Chromosome Gene ID Gene Description Change Parasite Line
4 Tb927.4.1330 DNA topoisomerase IB, large subunit partial ampliﬁcation 2
4 Tb927.4.1340 cleavage and polyadenylation speciﬁcity factor subunit, putative (CPSF3) ampliﬁcation 2
4 Tb927.4.1350 glyoxalase II, hydroxyacylglutathione hydrolase, putative (glx2-2) ampliﬁcation 2
4 Tb927.4.1360 hypothetical protein, conserved partial ampliﬁcation 2
6 Tb927.6.4400 # hypothetical protein, conserved deletion 3
6 Tb927.6.4410 # S-adenosylmethionine decarboxylase (AdoMetDC) deletion 3
6 Tb927.6.4420 hypothetical protein, conserved deletion 3
6 Tb927.6.4430 homoserine kinase, putative (HK) deletion 3
6 Tb927.6.4440 RNA-binding protein 42 (RNA-binding motif protein 42) (RBP42) deletion 3
6 Tb927.6.4450 ## hypothetical protein, conserved deletion 3
6 Tb927.6.4460 ## S-adenosylmethionine decarboxylase (AdoMetDC) deletion 3
10 Tb927.10.14620 * hypothetical protein, conserved deletion 3
10 Tb927.10.14630 * ﬁbrillarin, putative deletion 3
10 Tb927.10.14640 hypothetical protein, conserved deletion 3
10 Tb927.10.14650 hypothetical protein, conserved deletion 3
10 Tb927.10.14660 hypothetical protein, conserved deletion 3
10 Tb927.10.14670 hypothetical protein deletion 3
10 Tb927.10.14680 ribosome biogenesis protein, putative deletion 3
10 Tb927.10.14690 syntaxin, putative deletion 3
10 Tb927.10.14700 hypothetical protein, conserved deletion 3
10 Tb927.10.14710 40S ribosomal protein S2, putative (RPS2) deletion 3
10 Tb927.10.14720 peroxin 13,SH3 domain protein, conserved (PEX13) deletion 3
10 Tb927.10.14730 chaperone protein DNAj, putative deletion 3
10 Tb927.10.14740 ** hypothetical protein, conserved deletion 3
10 Tb927.10.14750 ** ﬁbrillarin, putative deletion 3
Note: Genes affected by CNVs of whole chromosomes (chromosomes 1 and 4 in clone 1/clone 1 revertant and clone 2, respectively) are not listed.
The genes marked with single and double hash symbols or single and double asterisks are part of regions that are approximately 99% identical to one
another, e.g. a 4.8kb-long region including Tb927.6.4400 and Tb927.6.4410 is 99% identical to a region including Tb927.6.4450 and Tb927.6.4460.
doi:10.1371/journal.pntd.0004299.t002
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be non-functional. In the other two clones, the SNPs are located at the C-terminus of the 114
residue peptide close to (Ala101Gly, clone 2) or adjacent to (Thr106Ile, clone 1) the site of
cleavage by ULP1/SENP which reveals a C-terminal di-glycine motif required for activation of
SUMO by the E1 activating complex [45]. Ala101 maps to a region predicted to interact with
the SUMO conjugating enzyme E2 (Ubc9) [47], but it is difficult to predict whether or not
such a conservative substitution with a glycine would significantly alter the interaction of the
enzyme with its substrate. Cells expressing Thr106Arg or Thr106Lys SUMOmutants have
been used in a proteomic study to successfully identify SUMO targets in T. brucei [48] so it
appears possible that an isoleucine would also be tolerated at this position. Furthermore, this
SNP is retained in the revertant clone, suggesting this mutation is not involved in resistance.
Nevertheless, it is possible that different resistance mechanisms may have arisen in each of
these lines. None of the genes potentially involved in SUMOylation [49] were found in com-
mon with either our proteomic or our genomic studies. However, of the 44 proteins identified
as SUMOylated in a previous study [48], one gene Tb927.4.1330 (DNA topoisomerase 1B,
large subunit) was identified as duplicated in resistant clone 2 (Table 2). This 90 kDa protein
has 4 SUMOylation sites [48] and forms a functional heterodimer with a 36 kDa catalytic sub-
unit and is essential for growth of the parasite [50]. However, it is noteworthy that topoisomer-
ase-IIα, a SUMOylated protein in other organisms, is essential in bloodstream form T. brucei
for centromere-specific topoisomerase cleavage activity [48], but was not present in any of our
candidate lists
Another candidate in the genome sequencing data, T. brucei homoserine kinase, has
recently been studied in our laboratory in relation to de novo synthesis of threonine [51]. The
recombinant enzyme was completely insensitive to inhibition by Oxaborole-1 (up to 50 μM)
and therefore is not the target for this compound. To investigate if the deletion of a copy homo-
serine kinase (CNV in resistant line 3, Table 2) was implicated in resistance, the sensitivity to
Oxaborole-1 in wild-type (WT), single knockout (SKOPAC) and double knockout (DKO)
bloodstream forms was determined. The resulting EC50 values were all within experimental
error of each other (41.1 ± 1.6, 36.1 ± 1.3 and 37.5 ± 1.5 nM for WT, SKOPAC and DKO,
respectively). Taken together, we can conclude that HSK is neither the target nor a resistance
determinant for oxaborole compounds.
This list of candidate mode of action genes, affected either by CNVs or the presence of
SNPs, is too long to be systematically investigated. Since no genes are common to both the
proteomic studies and the resistant studies, genes involved in resistance mechanisms would
appear to be distinct from candidate proteins implicated in the mode of action. In addition, the
genomic variations we have observed could be the result of either oxaborole exposure or an
unidentified resistance mechanism resulting in a general loss of DNA fidelity.
In conclusion, genetic analysis of laboratory-generated resistant lines has been an effective
technique when the field can be narrowed to particular genes of interest as in the case of resis-
tance of T. brucei to tRNA synthetase inhibitors resulting from overexpression of the target
[43]. However, taking an unbiased whole genome sequencing approach alongside the analysis
of oxaborole-binding proteins in the current study, has revealed too many candidates to
embark on a systematic appraisal.
Our SILAC-based analysis suggests considerable polypharmacology consistent with the
unusually long time taken to develop resistance, apparent multiple routes to resistance and
lack of stability in at least one of those routes. It should be borne in mind that resistance and/or
mode of action may involve several candidates acting in concert.
The surprising number of large-scale genomic aberrations in our resistant cell lines (Fig 5),
and the accumulation of cells in G2/>G2 (Fig 3) suggest DNA fidelity as an area of specific
interest. The presence of SNPs in the gene for SUMO (S2 Table) is particularly striking as its
Studies on the Mode of Action of Oxaboroles
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004299 December 18, 2015 14 / 18
repertoire of targets includes proteins involved in chromatin structure and DNA repair [52].
Future work will involve selecting candidates to test by protein modulation and sensitivity to
oxaboroles in the whole cell.
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